Lana McClements
Dunja Aksentijevic
Vesna Garovic- 1School of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, NSW, Australia
- 2Centre for Biochemical Pharmacology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
- 3Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN, United States
- 4Division of Nephrology and Hypertension, Department of Obstetrics and Gynaecology, Mayo Clinic College of Medicine, Rochester, MN, United States
Editorial on the Research Topic
New Technologies for Women’s Health
Introduction
Over the last decade, sex differences have been widely explored and have demonstrated the importance of understanding women’s and men’s health in the context of population health as a whole. These differences start in-utero, where male foetuses are larger by the second semester, whilst maternal immune response is stronger towards a male foetus creating a more pronounced pro-inflammatory environment compared to a female foetus. Male foetuses are also at higher risk of infection that can lead to premature birth (Inkster et al., 2021). In this Research Topic “New Technologies for Women’s Health,” we focused on emerging technologies and discoveries specific to women’s health that includes eleven articles divided into four themes: ovarian cancer (2), pregnancy (4), preeclampsia (3) and digital technologies (2).
Ovarian Cancer (2)
Two articles have been published related to ovarian cancer research. One describes innovative three D (3D) cellular technologies for modelling of ovarian cancer, which can be used to accelerate discovery towards implementation of personalized medicine Yee et al. Ovarian cancer is a heterogenous disease with different subtypes, some of them, such as high grade serous ovarian cancer, poorly responding to currently available therapies. 3D modelling systems of ovarian cancer can recapitulate cell-cell and cell-microenvironment interactions better than 2D, hence improving chances of successful translation of emerging treatments and improving responses of particular ovarian cancer subtypes to available therapies. The second article Hossain et al. outlines novel approaches to biomarker discovery for early diagnosis of ovarian cancer, which is an area of unmet clinical need. Potential candidates were discussed including circulating miRNA and cell-free DNA (cf-DNA), exosomes, and Chloride Intracellular Ion Channels (CLIC) family of proteins.
Pregnancy-Related Research and Technologies (4)
This sub-theme covers a wide range of research during pregnancy. For example, Bertini et al. is a systematic review of machine learning approaches for prediction of complications in pregnancy. The data collection methods included electronic medical records, medical images, biological markers, and to a lesser extent, sensors and foetal heart rate. They concluded that the machine learning approach was the most effective when using medical images for prediction of preterm birth and neonatal mortality.
Ghamrawi et al. compared methylation status in pregnancy using buffy coat DNA vs. DNA isolated from polymorphonuclear (PMN) and lymphocytic fractions obtained within 24 h prior to delivery from 29 normotensive pregnant women. Their study determined that buffy coat DNA rather than lymphocytic DNA is more representative of methylation patterns in white blood cells during normal pregnancy.
A retrospective cohort study reported on the effectiveness of fetoscopic laser coagulation in ameliorating the metabolomic alteration caused by twin-twin transfusion syndrome in placental tissue and cord plasma Liu et al. They also state that these altered metabolites are involved mainly in fatty acid and lipid-like molecule metabolism and that certain lipids and lipid-like molecules are correlated with neonatal birth weight or ejection fraction.
Novel therapeutic strategies involving an anti-oxidant and anti-inflammatory agent, dendrimer-based N-acetyl cysteine (DNAC), were evaluated in Liu et al. in terms of its ability to ameliorate placental inflammation, as a key cause of preterm birth and post-pregnancy adverse health consequences. The results of this in vivo study demonstrated that DNAC reduced the M1 pro-inflammatory macrophage cell subpopulation whilst increasing M2 anti-inflammatory macrophages, hence improving the placental immune profile in the intrauterine inflammation model.
Preeclampsia (3)
Preeclampsia is the leading cause of mortality and morbidity in pregnancy, yet currently this pregnancy-specific hypertensive disorder does not have a cure (Thornton et al., 2013). Better understanding of the pathogenic mechanisms leading to preeclampsia, particularly those affecting placental health, is key to developing better management strategies for preeclampsia. In this meta-analysis, Cirkovic et al. using publically available data, a number of placental miRNAs were identified as having the most promising role in the pathogenesis of preeclampsia. These included placental miRNA-16, miRNA-20b, miRNA-23a, miRNA-29b, miRNA-155 and miRNA-210, miRNA-376c, and peripheral blood miRNA-155 and miRNA-16; the vast majority of these were increased except for miRNA-376c and miRNA-16, which were found to be decreased in preeclampsia.
On the other hand, another study Freimane et al. performed a systematic review that identified the most promising biomarker candidates for early pregnancy prediction of preeclampsia risk in women with type 1 diabetes mellitus (T1DM). Pregnant women with T1DM have a four-fold increased risk of developing preeclampsia (Weissgerber and Mudd, 2015). This important review discussed 32 biomarkers, suggesting that first trimester HbA1c, urinary albumin, neutrophil gelatinase-associated lipocalin and adipokines likely have the best potential for prediction of preeclampsia in women with T1DM. These biomarkers are reflective of glycaemic control, insulin resistance and renal function.
Given that there are no effective treatments for preeclampsia, the research community has been focused on developing potential therapeutic strategies. In this review Murray et al. discussed an immunomodulatory treatment strategy that targets the CD4+ T cell mechanism. This mechanism-based approach associated with preeclampsia targets placental inflammation (Aneman et al., 2020), which, if ameliorated, could improve spiral artery invasion, placentation, and maternal tolerance.
Digital Technologies for Women’s Health (2)
Digital health and remote monitoring technologies are rapidly emerging for women’s health application and could be useful particularly for high-risk pregnancies requiring close surveillance. One such application includes the management of gestational diabetes mellitus, which affects around 1 in 8 pregnant women (Hod et al., 2015). This systematic review Bertini et al. outlines the benefits of remote monitoring technologies including: improved glycaemic control, increased satisfaction and acceptability, maternal confidence, decreased gestational weight gain, knowledge of gestational diabetes mellitus, and improved medical team time management.
An article Hurst B. S. et al. in our Research Topic also reported the accuracy of a novel skin-worn sensor and its associated algorithm in determining the fertile window and absence of ovulation in 80 women. This innovative skin-sensor was compared directly to a vaginal sensor and its algorithm, showing that it could be a useful tool for women with ovarian dysfunction who are trying to conceive.
Conclusion
In summary, this Research Topic on “New Technologies for Women’s Health” presents articles on different types of conditions affecting women, from challenges with conception to pregnancy complications and ovarian cancer. These articles describe breakthrough science and innovative technologies that could improve the health of women globally.
Author Contributions
LM wrote the manuscript. DA and VG edited the manuscript. All authors read and approved the final version.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Aneman, I., Pienaar, D., Suvakov, S., Simic, T. P., Garovic, V. D., and McClements, L. (2020). Mechanisms of Key Innate Immune Cells in Early- and Late-Onset Preeclampsia. Front. Immunol. 11, 1864. Front Immunol [Internet]Available from: https://www.frontiersin.org/article/10.3389/fimmu.2020.01864/full. doi:10.3389/fimmu.2020.01864
Hod, M., Kapur, A., Sacks, D. A., Hadar, E., Agarwal, M., Di Renzo, G. C., et al. (2015). The International Federation of Gynecology and Obstetrics (FIGO) Initiative on Gestational Diabetes Mellitus: A Pragmatic Guide for Diagnosis, Management, and Care. Int. J. Gynaecol. Obstet. [Internet][cited 2017 Aug 21];131 Suppl 3:S173-211. Available from: http://doi.wiley.com/10.1016/S0020-7292(15)30007-2.
Inkster, A. M., Fernández-Boyano, I., and Robinson, W. P. (2021). Sex Differences Are Here to Stay: Relevance to Prenatal Care. Jcm 10 (13), 3000. Available from: https://www.mdpi.com/2077-0383/10/13/3000. doi:10.3390/jcm10133000
Thornton, C., Dahlen, H., Korda, A., and Hennessy, A. (2013). The Incidence of Preeclampsia and Eclampsia and Associated Maternal Mortality in Australia from Population-Linked Datasets: 2000-2008. Am. J. Obstet. Gynecol. 208 (6), 476.e1–5. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0002937813002378. doi:10.1016/j.ajog.2013.02.042
Weissgerber, T. L., and Mudd, L. M. (2015). Preeclampsia and Diabetes, [Internet]. Curr. Diab Rep. 15 (3), 9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25644816. doi:10.1007/s11892-015-0579-4
Keywords: women’s health, preeclampsia, ovarian cancer, pregnancy, 3D bio printing, biomarkers, miRNA, placenta
Citation: McClements L, Aksentijevic D and Garovic V (2022) Editorial: New Technologies for Women’s Health. Front. Bioeng. Biotechnol. 10:969389. doi: 10.3389/fbioe.2022.969389
Received: 14 June 2022; Accepted: 22 June 2022;
Published: 13 July 2022.
Edited and reviewed by:
Andrea Banfi, University of Basel, SwitzerlandCopyright © 2022 McClements, Aksentijevic and Garovic. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Lana McClements, lana.mcclements@uts.edu.au